Objective To study the safety and efficacy of the combination of rituximab and DHAP chemotherapy in patients with relapsed non-Hodgkin lymphoma(NHL). Methods To choose 16 patients with relapsed B-cell NHL as research objects, they were divided into two groups: treatment and control group. The treatment group(8 cases) received the combination of rituximab and DHAP chemotherapy; the control group (8 cases) received combination chemotherapy. The treatment was first infused a dose of rituximab (375 mg/m2) the day before receiving the DHAP chemotherapy, and such treatment being repeated for 4 ~ 6 times every other week. The DHAP chemotherapy lasts 4 ~ 6 cycles and twenty-one days in each cycle. The control group was primitively administrated 4 ~ 6 cycles of CHOP chemotherapy, methotrexate, Ara-C and etoposide as additional drug. Results The complete response and overall response rate were 75 % and 100 % while in the control group were 37.5 % and 62.5 %. The progression-free and overall survival was (18.3?5.4) months significantly higher than that of the control group [(4.7?2.8) months, P

Objective To discuss the correlation between female chronic pelvic pain and pelvic floor anatomy.Methods The female patiems of chronic pelvic pain 179 cases,age 28-67 years,average 49.4 years;pelvic pain history 8 months-9 years,average 2.8 years;167 cases has childbirth history,43 cases has surgery history,which gynecological surgery 31 cases,and urinary surgery 7 cases,and anus surgery 5 cases.Results High incidence of female pelvic pain were 30-60 age (incidence of 54.8％),93.3％ has birth history,24％ has operation history,the myofascial tissue pain higher than the organ,were 87.4％ than 12.6％ (P ＜ 0.01),the front of pelvic pain higher than back,were 65.6％ than 21.8％ (P ＜ 0.01).Conclusions Female chronic pelvic pain associated with the particularity of the pelvic anatomy and physiological,with the tissue of pelvic floor and urogenital diaphragm of primary injure and chronic inflammation is an important cause of chronic pelvic pain.